The Swiss biotech start-up Polaroid Therapeutics (PTx) has partnered with fiber development specialist SFM Limited (SFM) on development projects. The World Health Organization has recognized antimicrobial resistance (AMR) as a serious global health risk. Together, they hope to develop an improved antibacterial gelling fiber to address this issue.
The collaboration will be concentrated on creating a new carboxymethyl cellulose (CMC) dressing that uses the exclusive Antimicrobial Polymer Technology (APT) of PTx. The goal of SFM’s trials is to create a novel wound dressing that inhibits infections and accelerates healing by incorporating PTx’s APT into CMC fibers.
“We at Polaroid Therapeutics believe AMR demands our urgent and focused attention,” said Ran Frenkel, CEO and co-founder of the company. By collaborating with a flexible and creative business like SFM, we can take on this global health issue head-on. By combining SFM’s cutting-edge fibers with our innovative antibacterial technology, our combined expertise seeks to revolutionize wound treatment.”
This strategic alliance makes use of the polymeric antibacterial technology based on quaternized polyethyleneimine (QPEI) developed by Polaroid Therapeutics. They hope to develop a ground-breaking wound-healing system that lowers the risk of infection and enhances the general health of patients with cavity wounds when combined with SFM’s CMC fiber technology. The partnership takes care of all the requirements for comprehensive wound care, such as efficient exudate management, infection prevention, moisture equilibrium, and patient compliance.
